Select Publications

Preprints

Aggarwal A; Stella A; Akerman A; Walker G; Milogiannakis V; McAllery S; Esneau C; Silva MR; Lu Y; Forster C; Hal SV; Mathivanan V; Fitcher C; Hoppe AC; Munier ML; Darley D; Matthews G; Starck D; Robosa R; Bartlett N; Rawlinson W; Kelleher A; Turville S, 2022, Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variants, http://dx.doi.org/10.21203/rs.3.rs-1210846/v1

Loo L; Waller M; Cole A; Stella AO; Moreno C; Denes C; Hamoudi Z; Chung F; Aggarwal A; Low J; Patel K; Siddique R; Mackay J; Turville S; Hesselson D; Neely G, 2021, LRRC15 suppresses SARS-CoV-2 infection and controls collagen production, http://dx.doi.org/10.1101/2021.11.09.467981

Johansen-Leete J; Ullrich S; Fry S; Frkic R; Bedding M; Aggarwal A; Ashhurst A; Ekanayake K; Mahawaththa M; Sasi V; Passioura T; Larance M; Otting G; Turville S; Jackson C; Nitsche C; Payne R, 2021, Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display, http://dx.doi.org/10.1101/2021.08.23.457419

Counoupas C; Pino P; Stella A; Ashley C; Lukeman H; Bhattacharyya N; Tada T; Anchisi S; Metayer C; Martinis J; Aggarwal A; Dcosta B; Kint J; Wurm M; Landau N; Steain M; Turville S; Wurm F; David S; Triccas J, 2021, Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens, http://dx.doi.org/10.1101/2021.08.18.456891

Ashhurst AS; Tang AH; Fajtová P; Yoon M; Aggarwal A; Stoye A; Larance M; Beretta L; Drelich A; Skinner D; Li L; Meek TD; McKerrow JH; Hook V; Tseng C-TK; Turville S; Gerwick WH; O'Donoghue AJ; Payne RJ, 2020, Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L., http://dx.doi.org/10.1101/2020.12.23.424111

Norman A; Franck C; Christie M; Hawkins P; Patel K; Ashhurst A; Aggarwal A; Low J; Siddiquee R; Ashley C; Steain M; Triccas J; Turville S; Mackay J; Passioura T; Payne R, 2020, Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein using mRNA Display, http://dx.doi.org/10.1101/2020.12.22.424069

Counoupas C; Johansen M; Stella A; Nguyen D; Ferguson A; Aggarwal A; Bhattacharyya N; Grey A; Patel K; Siddiquee R; Stewart E; Feng C; Hansbro N; Palendira U; Steain M; Saunders B; Low J; Mackay J; Kelleher A; Britton W; Turville S; Hansbro P; Triccas J, 2020, A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilizing immunity against SARS-CoV-2 infection in mice, http://dx.doi.org/10.1101/2020.12.10.419044

Lau D; Walsh J; Dickson C; Tuckwell A; Stear J; Hunter D; Bhumkar A; Shah V; Turville S; Sierecki E; Gambin Y; Böcking T; Jacques D, 2020, Rapid HIV-1 capsid interaction screening using fluorescence fluctuation spectroscopy, http://dx.doi.org/10.1101/2020.11.13.382242

Wong AKH; Mathivanan V; Di Giallonardo F; Ahlenstiel C; Turville SG, A Molecular Basis for the Increased Transmission of Ebolavirus in Recent Outbreaks, http://dx.doi.org/10.2139/ssrn.3507710

Garcia-Valtanen P; Hope CM; Masavuli MG; Lip Yeow AE; Balachandran H; Mekonnen ZA; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Gummow J; Ferguson C; O’Connor S; McCartney EM; Lynn DJ; Maddern G; Gowans EJ; Reddi BAJ; Shaw D; Kok-Lim C; Turville SG; Beard MR; Weiskopf D; Sette A; Bull RA; Barry SC; Grubor-Bauk B, COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection, http://dx.doi.org/10.1101/2021.11.08.21266035

Shen Y; Freeman JA; Holland J; Solterbeck A; Naidu K; Soosapilla A; Downe P; Tang C; Kerridge I; Wallman L; Van Bilsen N; Milogiannakis V; Akerman A; Martins Costa Gomes G; Sandgren K; Cunningham AL; Turville S; Mulligan SP, COVID-19 Vaccine Failure in Chronic Lymphocytic Leukemia and Monoclonal B-Lymphocytosis; Humoral and Cellular Immunity, http://dx.doi.org/10.1101/2021.10.28.21265549

Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, http://dx.doi.org/10.1101/2022.07.22.22277947

Li L; Honda-Okubo Y; Huang Y; Jang H; Carlock MA; Baldwin J; Piplani S; Bebin-Blackwell AG; Forgacs D; Sakamoto K; Stella A; Turville S; Chataway T; Colella A; Triccas J; Ross TM; Petrovsky N, Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection, http://dx.doi.org/10.1101/2021.07.03.451026

Bull R; Abayasingam A; Balachandran H; Agapiou D; Rodrigo C; Keoshkerian E; Li H; Brasher N; Christ D; Rouet R; Burnett D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Brilot F; Mina M; Post J; Hudson B; Gilroy N; Dwyer D; Sasson S; Tea F; Pilli D; Tedla N; Lloyd A; Martinello M, Long-term persistence of neutralizing memory B cells in SARS-CoV-2, http://dx.doi.org/10.21203/rs.3.rs-92527/v1

Abayasingam A; Balachandran H; Agapiou D; Rodrigo C; Keoshkerian E; Li H; Brasher N; Christ D; Rouet R; Burnett D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Brilot F; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson S; Tea F; Pilli D; Tedla N; Lloyd AR; Martinello M; Bull RA; Group COSINS, Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2, http://dx.doi.org/10.2139/ssrn.3732365

Loo L; Waller M; Cole A; Stella A; Moreno C; Denes C; Hamoudi Z; Chung F; Aggarwal A; Low J; Patel K; Siddiquee R; Mackay J; Turville S; Hesselson D; Neely G, LRRC15 suppresses SARS-CoV-2 infection and controls collagen production, http://dx.doi.org/10.21203/rs.3.rs-1172665/v1

Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson S; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer D; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA, Maintenance of Broad Neutralising Antibodies and Memory B Cells 12 Months Post-Infection Is Predicted by SARS-CoV-2 Specific CD4+ T Cell Responses, http://dx.doi.org/10.2139/ssrn.3920641

Ashhurst A; Johansen M; Maxwell J; Ashley C; Aggarwal A; Siddiquee R; Miemczyk S; Nguyen D; Mackay J; Counoupas C; Byrne S; Turville S; Steain M; Triccas J; Hansbro P; Payne R; Britton W, Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice, http://dx.doi.org/10.21203/rs.3.rs-1179181/v1

Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Kidinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Yeang M; Jean T; Foster C; Hoppe AC; Munier ML; Darley DR; Churchill M; Starck D; Christ D; Matthews G; Rawlinson W; Kelleher A; Turville S, SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern, http://dx.doi.org/10.2139/ssrn.4157473

Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Kidinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Coppola G; Yeang M; Jean T; Foster C; Hoppe AC; Ling Munier CM; Darley D; Churchill M; Starck D; Christ D; Matthews G; Rawlinson W; Kelleher AD; Turville S, SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.1101/2022.07.07.22277128

Aggarwal A; Stella AO; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Henry JY; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fichter C; Hoppe AC; Munier ML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher AD; Turville S, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.1101/2021.12.14.21267772


Back to profile page